samedan logo
 
 
spacer
home > ebr > winter 2003 > future of electronic data capture in clinical trials
PUBLICATIONS
European BioPharmaceutical Review

Future of Electronic Data Capture in Clinical Trials

Clinical trials currently account for approximately 70 per cent of the US$403 million cost involved in bringing a new drug to market. This makes them an obvious target for those wanting to reduce drug discovery and development costs. The following scenario takes place in the future and suggests how technology may change the process.

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tony Dean, Director of Sales and Marketing at Datatrial Ltd

Tony Dean is Director of Sales and Marketing at Datatrial, a biometrics CRO. Tony graduated in Applied Biology and began working in the pharmaceutical industry in 1979 with SK&F, working at the bench in drug metabolism and pharmacokinetics. He subsequently moved into the CRO sector and held various positions within clinical project management prior to moving into business development five years ago.

spacer
Tony Dean
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

New PFA SonicLineŽ ultrasonic flowmeters

Flow measurement with ultrasound fast, precise, free from contamination         The new PFA SonicLineŽ ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLineŽ is also ideally suited for accurate batch and dosing processes with high reproducibility.              
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement